• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PD-1 is highly expressed by neoplastic B-cells in Richter transformation.

作者信息

Behdad Amir, Griffin Brannan, Chen Yi-Hua, Ma Shuo, Kelemen Katalin, Lu Xinyan, Chen Qing C

机构信息

Department of Pathology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.

出版信息

Br J Haematol. 2019 Apr;185(2):370-373. doi: 10.1111/bjh.15514. Epub 2018 Jul 20.

DOI:10.1111/bjh.15514
PMID:30028010
Abstract
摘要

相似文献

1
PD-1 is highly expressed by neoplastic B-cells in Richter transformation.在Richter转化中，肿瘤性B细胞高表达程序性死亡受体1（PD-1）。
Br J Haematol. 2019 Apr;185(2):370-373. doi: 10.1111/bjh.15514. Epub 2018 Jul 20.
2
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.PD-1 在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 (CLL/SLL) 和大 B 细胞 Richter 转化 (DLBCL-RT) 中的表达：DLBCL-RT 的特征性特征和潜在的克隆相关性替代标志物。
Am J Surg Pathol. 2018 Jul;42(7):843-854. doi: 10.1097/PAS.0000000000001077.
3
Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.慢性淋巴细胞白血病和里希特综合征的免疫特征不同。
Blood Cancer J. 2021 May 10;11(5):86. doi: 10.1038/s41408-021-00477-5.
4
Clinicopathological Study of PD-1/PD-L1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation.慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）中 PD-1/PD-L1 表达的临床病理研究，重点是大 B 细胞 Richter 转化。
Asian Pac J Cancer Prev. 2023 Dec 1;24(12):4243-4252. doi: 10.31557/APJCP.2023.24.12.4243.
5
Richter's transformation in the heart.心脏里的 Richter 转化
Lancet Oncol. 2021 Jul;22(7):e341. doi: 10.1016/S1470-2045(21)00153-4.
6
Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.程序性死亡受体-1 及其配体是慢性淋巴细胞白血病白血病 B 细胞上表达的新型免疫耐受分子。
PLoS One. 2012;7(4):e35178. doi: 10.1371/journal.pone.0035178. Epub 2012 Apr 19.
7
PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.EBV 阴性弥漫性大 B 细胞淋巴瘤中 PD-L1 的表达：临床病理特征及预后意义
Oncotarget. 2016 Sep 13;7(37):59976-59986. doi: 10.18632/oncotarget.11045.
8
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression.伴有不寻常CD2和PD-1表达的慢性淋巴细胞白血病的TP53/PLCG2突变型弥漫性大B细胞淋巴瘤 Richter转化（DLBCL-RT）
Leuk Lymphoma. 2022 Nov;63(11):2735-2738. doi: 10.1080/10428194.2022.2087070. Epub 2022 Jun 18.
9
Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides.免疫抑制蛋白PD-1/CD279和PD-L1/CD274在皮肤T细胞淋巴瘤/蕈样肉芽肿不同阶段的表达模式
Am J Dermatopathol. 2012 Feb;34(1):126-8. doi: 10.1097/DAD.0b013e31821c35cb.
10
Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings.PD-1 和 PD-L1 分子在未特指的弥漫性大 B 细胞淋巴瘤患者中的临床意义：与临床和病理发现的相关性。
J BUON. 2021 Mar-Apr;26(2):569-579.

引用本文的文献

1
A question of TiME: how microenvironmental interactions shape response to immunotherapy in CLL and Richter Transformation.时间问题：微环境相互作用如何塑造慢性淋巴细胞白血病和Richter转化对免疫疗法的反应
Front Immunol. 2025 May 29;16:1592574. doi: 10.3389/fimmu.2025.1592574. eCollection 2025.
2
Updates on the Treatment of Richter's Syndrome, Including Novel Combination Approaches.里氏综合征的治疗进展，包括新型联合治疗方法
Cancers (Basel). 2025 Mar 11;17(6):943. doi: 10.3390/cancers17060943.
3
Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.
惰性B细胞恶性肿瘤向侵袭性B细胞恶性肿瘤转变的分子机制
Cancers (Basel). 2025 Mar 6;17(5):907. doi: 10.3390/cancers17050907.
4
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.阿替利珠单抗联合免疫原性挽救性化疗免疫疗法治疗转化型弥漫性大B细胞淋巴瘤患者。
Haematologica. 2025 Jan 1;110(1):142-152. doi: 10.3324/haematol.2024.285185.
5
Clinicopathological Study of PD-1/PD-L1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation.慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）中 PD-1/PD-L1 表达的临床病理研究，重点是大 B 细胞 Richter 转化。
Asian Pac J Cancer Prev. 2023 Dec 1;24(12):4243-4252. doi: 10.31557/APJCP.2023.24.12.4243.
6
Richter Transformation of Chronic Lymphocytic Leukemia-Are We Making Progress?慢性淋巴细胞白血病的 Richter 转化——我们是否取得了进展？
Curr Hematol Malig Rep. 2023 Oct;18(5):144-157. doi: 10.1007/s11899-023-00701-y. Epub 2023 Jun 9.
7
Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant.Richter 转化弥漫性大 B 细胞淋巴瘤变异型中常见免疫逃逸表型。
Virchows Arch. 2023 Jun;482(6):1011-1019. doi: 10.1007/s00428-023-03520-x. Epub 2023 Mar 3.
8
Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy.里氏综合征的免疫学方面：从免疫功能障碍到免疫治疗
Cancers (Basel). 2023 Feb 5;15(4):1015. doi: 10.3390/cancers15041015.
9
A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?复发或难治性非霍奇金淋巴瘤免疫检查点疗法的系统评价和荟萃分析：是友还是敌？
Transl Oncol. 2023 Apr;30:101636. doi: 10.1016/j.tranon.2023.101636. Epub 2023 Feb 9.
10
Richter syndrome: novel insights into the biology of transformation.里希特综合征：转化生物学的新见解。
Blood. 2023 Jul 6;142(1):11-22. doi: 10.1182/blood.2022016502.